Tue, Oct 21, 2014, 5:11 AM EDT - U.S. Markets open in 4 hrs 19 mins


% | $
Quotes you view appear here for quick access.

Geron Corporation (GERN) Message Board

  • astrogern astrogern Oct 5, 2013 9:10 AM Flag


    Purpose: Imetelstat is a covalently-lipidated 13-mer thiophosphoramidate oligonucleotide that acts as a potent specific inhibitor of telomerase. It binds with high affinity to the template region of the RNA component of human telomerase (hTERC ) and is a competitive inhibitor of telomerase enzymatic activity. The purpose of this study was to determine the recommended phase 2 dose of imetelstat in children with recurrent or refractory solid tumors. Experimental Design: Imetelstat was administered intravenously over two hours on days 1 and 8, every 21 days. Dose levels of 225, 285, and 360 mg/m2 were evaluated, using the rolling-six design. Imetelstat pharmacokinetic and correlative biology studies were also performed during the first cycle. Results: Twenty subjects were enrolled (median age 14 yrs; range 3-21). Seventeen were evaluable for toxicity. The most common toxicities were neutropenia, thrombocytopenia, and lymphopenia, with dose-limiting myelosuppression in two of six patients at 360 mg/m2. Pharmacokinetics were dose dependent with a lower clearance at the highest dose level. Telomerase inhibition was observed in peripheral blood mononuclear cells at 285 and 360 mg/m2. Two confirmed partial responses osteosarcoma (n=1) and Ewing sarcoma (n=1) were observed. Conclusions: The recommended phase 2 dose of imetelstat given on days 1 and 8 of 21-day cycle is 285 mg/m2.
    Received May 8, 2013.
    Revision received September 10, 2013.
    Accepted September 11, 2013.
    Copyright © 2013, American Association for Cancer Research Less
    Sort: Newest | Oldest | Most Replied Collapse all replies
    qed2013 • 1 hour 11 minutes ago
    1users liked this postsusers disliked this posts0Reply
    I don't fully understand the abstract implications, nor know the changes from the May 8th receipt, to the Sept 11th acceptance of revisions, but Sept 10th/11th GERN was trading $1.60, it has more than doubled in an almost straight-line fashion.
    Sentiment: Strong Buy

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.18+0.07(+3.32%)Oct 20 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.